Researchers from Boston-based Massachusetts General Hospital examined 12 patients who developed a rash at the injection site eight or more days after receiving their first dose of Moderna’s COVID-19 vaccine. Their symptom onset ranged from four days after receiving their first dose to up to 11 after receiving their first dose.
The patients’ rashes varied in size and severity. Ice and antihistamines treated most patients’ rashes, but some required corticosteroids and one erroneous case was treated with antibiotics, according to the study.
Half of the patients experienced a rash after receiving their second dose around 48 hours after getting the shot, but none of them experienced a reaction that was more severe than their first dose reaction.
“Whether you’ve experienced a rash at the injection site right away or this delayed skin reaction, neither condition should prevent you from getting the second dose of the vaccine,” Kimberly Blumenthal, MD, the study’s lead author and co-director of Massachusetts General Hospital’s clinical epidemiology program, said in a news release. “Our immediate goal is to make physicians and other care providers aware of this possible delayed reaction, so they are not alarmed, but instead well-informed and equipped to advise their patients accordingly.”
More articles on pharmacy:
2 Memorial Health System pharmacists fired after one took COVID-19 vaccines home for family
NIH halts convalescent plasma trial in patients with moderate COVID-19 symptoms
US vaccinating 2 million people per day
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
